Stroke
January 2014
Methods

EPIC-Potsdam Study
Study Population
EPIC-Potsdam study comprises 27 548 individuals from the general population of the Potsdam area (Germany). 8 The association of plasma total-adiponectin with risk of IS was analyzed using a case-cohort design. The study-set included all incident IS cases that occurred during a mean follow-up of 8.2±2.2 years 9 and a random subcohort (n=2500). When both IS and myocardial infarction (MI) occurred in the same participant (n=5), we only considered the first event. IS occurred before MI in 2 cases and MI before IS in 2 more. One participant had a stroke and MI on the same day; the MI was prioritized over stroke. After exclusion of individuals because of prevalent IS or MI, missing follow-up, or missing adiponectin or covariate information, the final study population comprised a subcohort of 2155 participants and 170 IS cases (11 being fatal and 27 belonging to the subcohort). A total of 605 participants were fasting for ≥8 hours before the blood draw. Informed consent was obtained from all study participants. The study was approved by the Ethical Committee of the state of Brandenburg, Germany.
Biochemical Analyses
Baseline plasma levels of biomarkers were measured at Tübingen University (Germany) in samples retrieved from frozen storage (2007) (2008) . Adiponectin was determined with an ELISA (Linco Research, St Charles, MO; intra-assay and interassay coefficients of variation, 0.1%-6.2% and 5.0%, respectively). High-density lipoprotein-cholesterol, triglycerides, high-sensitivity C-reactive protein, and creatinine were determined with the Siemens ADVIA 1650. N-terminal probrain-type natriuretic peptide was measured in all incident IS cases and in a random subsample of 1137 subcohort members (attributable to financial restrictions) at the Institute of Clinical Chemistry, University of Magdeburg (2012) with an electrochemiluminescence immunoassay on the Immulite analyzer (Siemens AG, Munich, Germany).
Statistical Analysis
Because women had higher total-adiponectin levels than men, baseline characteristics were cross-sectionally compared across sex-specific total-adiponectin tertiles based on the distribution among the subcohort, by age-adjusted ANOVA.
Association of total-adiponectin with risk of IS was calculated as hazard ratios using Cox proportional-hazard regression, modified according to Prentice, 10 using a robust estimator to compute the 95% confidence interval. Age was the underlying time metric. HRs were estimated per 5-µg/mL higher total-adiponectin and according to sex-specific tertiles of total-adiponectin in the subcohort. HRs were adjusted for sex (M1); further for common cardiovascular risk factors (waist circumference, smoking, sports activity, education, alcohol consumption, prevalent hypertension, M2); and further for fasting status and for metabolic factors that have been suggested to be intermediate factors 11 (diabetes mellitus, high-density lipoproteincholesterol, triglycerides, and high-sensitivity C-reactive protein, M3).
Effect modification by sex and by age were, respectively, evaluated by modeling the product-term sex times total-adiponectin, and age times total-adiponectin along with the main effects in the Coxregression. Sensitivity analyses were performed after excluding fatal IS cases; participants with total-adiponectin below/above the population-wide lower/upper deciles; with prevalent chronic diseases; central obesity; taking antihypertensive, antidiabetic or lipid-lowering medication; those >60 years; smokers or alcohol consumers. Also the first 4 years of follow-up were excluded to account for latency.
MI shares the atherosclerotic pathophysiological pathway with IS. Because we focus on IS here, HRs of MI per 5-µg/mL higher adiponectin are presented in Table I in the online-only Data Supplement. Identification and verification of incident MI cases have been described elsewhere. 9 Study design, exclusion criteria, and adjustment models were the same as used for IS.
Meta-analysis of Prospective Studies
Meta-analysis of Observational Studies in Epidemiology guidelines 12 were applied (Table II in [Mesh] or prospective or nested or cohort). The equivalent search was constructed for EMBASE. Reference lists of retrieved articles were hand-searched for additional studies. Data gathered included: first author, publication year, location, study design, race/ethnicity, number of participants, proportion of women, duration of followup, age, adiponectin assay, mean adiponectin levels and body mass index among noncases, number of cases, case ascertainment, variables controlled for and comparison used.
Effect estimates were extracted for the least and most adjusted models, with and without inclusion of presumed mediators. We contacted authors when data needed for the dose-response meta-analysis were incompletely reported. [13] [14] [15] Study-specific dose-response associations were calculated per 5-µg/mL higher adiponectin concentration by using the generalized least squares for trend estimation method, to combine comparable estimates with random-effect meta-analysis. Heterogeneity between-study results was evaluated by using the I 2 statistic. Publication bias was investigated by Egger test and by visual inspection of the funnel plot. An influential analysis was performed by omitting 1 study at a time. Statistical analyses were performed using SAS Enterprise Guide 4.3 (SAS Institute Inc, Cary, NC) and STATA SE version 12.1 (StataCorp, College Station, TX).
Results
EPIC-Potsdam Study
Baseline Characteristics of Participants Baseline median (interquartile range) total-adiponectin levels in men and women were 5.6 (4.15-7.36) and 8.6 (6.32-11.40) µg/mL, respectively. Baseline characteristics of the subcohort across adiponectin tertiles are shown in Table 1 separately for men and women. Compared with those in the lower tertiles, men and women in the highest tertiles were slightly older and showed better cardiovascular profiles. Table 2 shows HRs of incident IS per 5-µg/mL higher totaladiponectin, and across sex-specific tertiles of adiponectin. No significant associations were found after adjustment for sex and common cardiovascular risk factors. After additional adjustment for potential mediators, including high-density lipoprotein-cholesterol, high-sensitivity C-reactive protein, and diabetes mellitus, adiponectin was directly associated with IS risk. Adjustment for creatinine, a crude estimate of renal function, yielded essentially similar HRs. Adjustment for N-terminal probrain-type natriuretic peptide, a discerning marker for heart damage, only slightly attenuated the HRs (data not shown). The association between adiponectin and stroke did not differ by sex (P interaction=0.4) or age (P interaction=0.1) after adjustment for variables in M2 (Table III in 
Adiponectin and Incident Stroke
Meta-analysis of Prospective Studies
Sixty-four hits from EMBASE and 82 from MEDLINE were retrieved. After exclusion of duplicates and of articles that did not meet the inclusion criteria ( Figure I in the onlineonly Data Supplement), 9 articles 11, [13] [14] [15] [16] [17] [18] [19] [20] reporting results for 8 independent study populations were eligible for inclusion. Nine studies, 11, [13] [14] [15] [16] [18] [19] [20] including EPIC-Potsdam, reported on total-adiponectin. The Cardiovascular Health Study 11 and the Women's Health Initiative Study 17, 18 reported also on HMW-adiponectin, with findings being similar to totaladiponectin. Therefore, our analysis includes risk estimates of total-adiponectin only. Thus, together with the EPICPotsdam study, ≤9 independent studies were meta-analyzed ( (Table 4) . 16 Outcomes were total stroke, 14, 19, 20 IS, 11, 13, 15, 17, 18 or both. 16 For 1 study 13 that reported RR only for a subgroup of smokers, we calculated the crude odds ratio from the reported contingency table including participants. One study 14 provided separate RR for men and women (personal correspondence), and these were included in the analysis as separate RR. For another study, 11 we used a fixed-effects metaanalysis to combine the RRs corresponding to before and after the knot of the spline-regression. Before and after adjustment for potential mediators, adiponectin was significantly related to stroke risk only in 1 15 and 3 studies, 15, 19 including EPICPotsdam, respectively.
The Figure (A) shows the pooled multivariable-adjusted RR without adjustment for mediators. Initially, we observed moderate heterogeneity across study results (I 2 =52.2%; P=0.027). This was mainly driven by the smallest study, 15 which after exclusion reduced the I 2 statistic to 3.2% (P=0.41) and yielded a pooled RR of 0.99 (95% confidence interval, 0.96-1.01) per 5-µg/mL higher adiponectin. Similar to EPIC-Potsdam, combining RR additionally adjusted for potential mediators 
Figure.
Most completely adjusted relative risks (RRs) of stroke per 5-μg/mL higher circulating adiponectin in individual studies and combined across studies in dose-response random-effects meta-analysis before (A) and after (B) adjustment for potential intermediate factors. 95% confidence interval, 1.00-1.11) . The lack of symmetry of the funnel plot as well as Egger test (P<0.05) suggested lack of smaller studies reporting an inverse association between adiponectin and stroke.
Discussion
In EPIC-Potsdam, higher levels of total-adiponectin were associated with better metabolic profiles. In contrast, totaladiponectin tended to be positively associated with IS risk. Interestingly, this association became stronger and significant after controlling for metabolic markers that have been suggested to be intermediates. Although (putative) overadjustment may have produced spurious results, unknown pathways underlying the increased risk cannot be excluded. Results of our meta-analysis based on 9 independent prospective studies extend those from 2 recent meta-analyses on the relationship between adiponectin and stroke, which included only 2 22 and 3 studies. 23 Our meta-analysis indicated lack of association between adiponectin and stroke risk. If anything, adiponectin was directly related to stroke risk after controlling for metabolic factors that favorably correlate with adiponectin.
A trend toward increased risk of coronary heart disease 11 and cardiovascular death 21,24 associated with higher adiponectin despite better metabolic profiles has also previously been observed in studies in older populations. One possible explanation is that the progression of cardiovascular diseases may lead to adiponectin resistance. 25 In the EPIC-Potsdam study, we excluded participants with a clinical history of major cardiovascular disease events at baseline. We also lagged the statistical analysis by 4 years to account for latency, which did not alter our results. It has also been suggested that the presence of diseases prompting to a hypercatabolic state may induce compensatory increased adiponectin levels. 26 Our findings, however, did not substantially change after excluding prevalent cases of several chronic diseases or controlling for creatinine, and adjusting for N-terminal probrain-type natriuretic peptide only slightly attenuated the risk estimates. Also, the better metabolic profiles associated with higher total-adiponectin would argue against these explanations. We focused on total-adiponectin and not on HMW-adiponectin, which is thought to be the most biologically active form. 27 Nevertheless, total and HMW-adiponectin have shown to be highly correlated, 11 and recent findings do not support HMWadiponectin to be more strongly related to risk of stroke 11 or coronary heart disease. 28 Adiponectin levels increase with age, and this could be a critical factor in assessing the associations between adiponectin and cardiovascular end points. However, age did not modify the association between adiponectin and incident stroke in our study population, which age was mostly between 35 and 65 years. Finally, it has been suggested that very high levels of adiponectin could have harmful effects by means of the activation of complement mechanisms. 29 Limitations of our prospective study include that a single assessment of adiponectin may be susceptible to within-individual variation. Adiponectin concentrations, however, have shown to be quite stable over time. 30 Furthermore, only a third of the study population was in fasting status. However, adiponectin values did not differ according to fasting status, and adjusting for it did not affect our risk estimates.
The meta-analysis included studies that differed in population characteristics, methods, variables controlled for, and outcomes considered (total stroke/IS). However, we did not find that these factors influenced results across studies. Although we observed a potential risk for publication bias, it may be unnecessary to evaluate the existence of preferential publication when very few studies reported significant results.
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Summary
This prospective study and meta-analysis shows that circulating total-adiponectin does not relate to risk of stroke. If anything, adiponectin relates directly to stroke risk after controlling for metabolic factors that correlate favorably with adiponectin. The number of studies on HMW-adiponectin is limited, and no studies on other adiponectin fractions are available. Therefore, it remains unclear whether specific molecular-weight fractions of adiponectin may influence risk of stroke. those excluded, including justification ˗ Duplicates excluded: n = 42 ˗ Was not a prospective study: n = 1 ˗ Adiponectin was not the exposure: n = 43 ˗ Stroke was not the outcome: n = 24 ˗ Participants had already suffered a stroke: n = 6 ˗ Not healthy populations: n = 17 ˗ Review or meta-analysis: n = 4 ˗ Duplicity of study-population: n = 1 Tables 3-4 Figure 1 Table 3 . Characteristics of prospective studies investigating the association of adiponectin and incident stroke in apparently healthy populations Table 4 . Relative Risks of stroke according to adiponectin levels in prospective studies conducted in healthy populations Figure 1 . Relative risks and 95% confidence intervals of stroke per 5-µg/mL-increase of adiponectin across studies. RR for most adjusted models before (A) and after (B) potential intermediates Table 3   Table 3 . Characteristics of prospective studies investigating the association of adiponectin and incident stroke in apparently healthy populations
Reporting of results
Graphic
Results of sensitivity testing
ResultsSystematicreview and metaanalysis (7-8) Figure 1 Sensitivity analysis revealed that the high heterogeneity observed was mainly driven by the smallest study.
Indication of statistical uncertainty of findings
ResultsSystematicreview and metaanalysis Figure 1 95% confidence intervals were presented with all summary estimates
Reporting of discussion
Quantitative assessment of bias
ResultsSystematicreview and metaanalysis (8) The asymmetry of the funnel plot and Egger's test results (P<0.05) suggested lack of smaller studies reporting an an inverse association between adiponectin and stroke.
Justification for exclusion Supplementary figure I
Duplicates excluded: n = 42 Was not a prospective study: n = 1 Adiponectin was not the exposure: n = 43 Stroke was not the outcome: n = 24 Participants had already suffer a stroke: n = 6 Not healthy populations: n = 17 Review or meta-analysis: n = 4 Articles excluded due to duplicity of study population: n = 1 Assessment of ResultsWe discussed the potential reasons for the observed quality of included studies Systematicreview and metaanalysis (7) heterogeneity. There was strong diversity among studies in terms of populations, methodology, variables controlled for and outcomes considered, however it did not seem to strongly influence results across studies, as they were mostly quite consistent. Sensitivity analysis revealed that the high heterogeneity observed was mainly driven by the smallest study
Reporting of conclusions
Consideration of alternative explanations for observed results
Summary (9)
There was large diversity among studies in terms of populations, methodology, variables controlled for and outcomes considered (TS/IS). Although we did not find that these factors influenced results across studies, this may be better investigated in a future larger meta-analysis.
Generalization of the conclusions
Summary (10) Current evidence does not support a relationship between total adiponectin and risk of stroke. The number of studies on HMWadiponectin and no studies reported on other adiponectin fractions. Therefore, it remains unclear whether specific molecular-weight fractions of adiponectin may influence risk of stroke. Guidelines for future research Summary (9) More studies on specific molecular weight fractions of adiponectin may shed further light on the role of adiponectin and risk of stroke.
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